Introducing a new medicine is a huge and complex task, especially when the medicine is being distributed in weak health systems and improper use can cause drug resistance. As I lay out in a commentary piece published today by the health policy journal Health Affairs, it will be critical to ensure that the roll-out of bedaquiline—the first novel TB drug approved in over 40 years, manufactured by Janssen Pharmaceutical—is properly managed, with efforts to build the capacity of health systems to distribute the drug as needed, and to educate physicians to administer it properly in all cases.